Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NYSE MKT | Common Stock
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally.
The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology.
Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme.
The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019.
Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.04 Decreased by -33.33% | -0.04 |
| Mar 7, 24 | -0.03 Increased by 0.00% | -0.04 Increased by +25.00% |
| Nov 9, 23 | -0.04 Increased by 0.00% | -0.04 |
| Aug 10, 23 | -0.03 Increased by +25.00% | -0.04 Increased by +25.00% |
| May 11, 23 | -0.03 Increased by +25.00% | -0.04 Increased by +25.00% |
| Mar 9, 23 | -0.03 Increased by +82.35% | -0.04 Increased by +25.00% |
| Nov 10, 22 | -0.04 Increased by +20.00% | -0.04 |
| Aug 11, 22 | -0.04 Decreased by -33.33% | -0.04 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.25 M Decreased by -58.44% | -7.11 M Decreased by -16.25% | Decreased by -570.63% Decreased by -179.71% |
| Jun 30, 23 | 3.23 M Decreased by -29.17% | -5.23 M Increased by +47.54% | Decreased by -162.14% Increased by +25.93% |
| Mar 31, 23 | 2.39 M Decreased by -54.44% | -4.40 M Increased by +46.92% | Decreased by -184.58% Decreased by -16.50% |
| Dec 31, 22 | 1.92 M Increased by +99.48% | -6.59 M Increased by +77.26% | Decreased by -344.23% Increased by +88.60% |
| Sep 30, 22 | 3.00 M Increased by +36.15% | -6.12 M Increased by +21.82% | Decreased by -204.00% Increased by +42.58% |
| Jun 30, 22 | 4.55 M Increased by +932.43% | -9.97 M Decreased by -108.17% | Decreased by -218.91% Increased by +79.84% |
| Mar 31, 22 | 5.24 M Increased by +1.69 K% | -8.30 M Decreased by -485.95% | Decreased by -158.43% Increased by +67.22% |
| Dec 31, 21 | 960.00 K Increased by +478.31% | -28.99 M Decreased by -1.53 K% | Decreased by -3.02 K% Decreased by -346.70% |